pushed out imo!
look for a real shift to RETAIL experience in the next CEO, and realistic M&A valuation on the asset!!
PS//if they sell the news I will be a buyer at the right P!
got my BUY
Yes, K was certainly pushed out. Last year's proxy fight outlined the problems and why we can still have a piece of this company for single digits. Obviously K's a research genius--no doubt--but she was lacking as a public-facing CEO and couldn't take the company beyond that. She deserves credit, though, for taking this RGI from research and development to a fully functioning, self-supporting and viable company. Early investors and believers deserve credit, too.
Now RGDX needs a really adept CEO who can tell the company's story and get all of Wall Street on board. And take us from break even to serious profitability. The trend is good. Exciting time to be here.
I want to thank KD personally for her tireless work ethic to bring her Thesis research into the clinic and give us shareholders of RGDX a company that one day may make us all quite proud and financially secure!
are you serious?
why would you believe this...pharma revenue is a fnc. of RGDX capability to do assay work in a timely and accurate fashion for their studies of NEW CANCER DRUGS or NEW INDICATIONS ON older drugs so why compromise the tissue bank RGDX has in various cancers?
that makes NO SENSE and yet I agree KD is a legend but this is a business and large pharma is out to exploit companion dignostics to accompany all the targeted agents they are creating!
RGDX is in a sweet spot and this quarter sales revs could be the first BE point!
therefore I have been a net buyer since trading out at 2.85 about 1/2 my previous 44K share position....
Unlikely, most of the CRO work is tied to ongoing trials. Pharma won't change labs during trials unless there is a quality or documentation issue. New CRO projects depend on the new management team's efforts. A service niche remains for access to assays migrating from "studies" to early adopters of the new biomarkers. RGDX's early involvement in companion diagnostic test development will, however, shift to the large IVD manufacturers that have developmental, regulatory, and sales capabilities.
More management changes! The VP of Regulatory Affairs has sent an email to colleagues announcing her resignation effective October 7th. This is not a required disclosure by the company but she was the most senior non-officer or Director posted on the Website.